Compounded semaglutide has not been banned in the United States as of this update, but the shortage-era allowance that made it widely available ended in 2025, and FDA has proposed excluding its bulk ingredient from the 503B clinical-need list [2] [5]. An individual prescription alone does not establish that all conditions for a lawful compounded preparation are met.
No ban, but the rules tightened in 2025
Semaglutide injection had been in shortage since 2022. On February 21, 2025, FDA determined “the shortage of semaglutide injection products … is resolved” [2]. Shortage resolution removed a shortage-dependent basis for exemption; other compounding conditions still require separate assessment.
The announced transition periods were later tied to litigation. After the court denied a preliminary injunction on April 24, 2025, FDA said the 503A enforcement-discretion period had ended; its 503B period continued to May 22, 2025. These were limited enforcement policies, not temporary FDA approval of compounded preparations. FDA retained authority to address other violations and unsafe products during the transitions [2].
For 503A, FDA highlights an individual-patient prescription and restrictions on compounding essentially copies regularly or in inordinate amounts. Its guidance describes discretion for four or fewer prescriptions of an essentially-copy product in a calendar month. That is not a statutory permission slip or exemption from other requirements. A prescriber-documented change producing a significant difference for an identified patient can affect the essentially-copy analysis; simply adding another ingredient does not automatically do so [2].
The 503B bulk-ingredient restriction is different. FDA says outsourcing facilities generally need the ingredient on its clinical-need list or the compounded drug on the shortage list at the relevant times. This concerns compounding from bulk substances, rather than establishing that every possible outsourcing-facility pathway is prohibited. The proposal addresses that list; it does not rewrite all of 503A [2] [4]. The safety guide and access guide separate product risks from prescribing and dispensing questions.
| Date | Event | Source |
|---|---|---|
| 2022 | Semaglutide injection goes into shortage | FDA [2] |
| February 21, 2025 | FDA declares the semaglutide shortage resolved | FDA [2] |
| March 10, 2025 | FDA ties the grace periods to the court’s decision date | FDA [2] |
| April 22, 2025 | Stated end of the 503A grace period | FDA [2] |
| April 24, 2025 | Court denies a preliminary injunction; 503A grace period ends | FDA [2] |
| May 22, 2025 | 503B grace period ends | FDA [2] |
| April 1, 2026 | FDA reminder: semaglutide is on neither the 503B bulks list nor the shortage list | FDA [2] |
| April 30, 2026 | FDA proposes not to include semaglutide on the 503B bulks list | FDA [4] |
| May 1, 2026 | Proposal published in the Federal Register | Federal Register [5] |
| May 31, 2026 | FDA reports 990 adverse-event reports associated with compounded semaglutide | FDA [3] |
| June 26, 2026 | Comment period extended to July 30 | Federal Register [6] |
| July 30, 2026 | Extended comment period closes | Federal Register [6] |
| As of this update | Reviewed proposal and extension are notices; search located those two records | Federal Register API [1] |
Dates are FDA’s and the Federal Register’s own. A “proposal” is not a final rule.
What FDA proposed in 2026
FDA announced its proposed clinical-need assessment on April 30, 2026. The Federal Register published the proposal May 1, followed by a June 26 notice extending comments through July 30. Both records are notices describing proposed noninclusion, not final approval or a blanket compounding prohibition [4] [5] [6].
The current Federal Register API search for semaglutide and 503B returned these two records. That is a documented search result, not proof that no other legal action exists. The reviewed FDA policy says semaglutide is absent from both the 503B bulks and shortage lists. A provider should explain the applicable basis for the actual product rather than treating a pending notice as permission to continue unchanged [1] [2].
Salt forms are already off-limits
One thing FDA has already settled: semaglutide sodium and semaglutide acetate. FDA says these salt forms “are different active ingredients than are used in the approved drugs” and that it is “not aware of any lawful basis for their use in compounding” [3]. If your pharmacy label says sodium or acetate, ask your prescriber about it before your next refill. Safety concerns in full are in is compounded semaglutide safe.
What a final decision would change, and what it wouldn’t
A final decision about the 503B bulks list would address that bulk-ingredient pathway. It would not by itself decide every 503A prescription or product. Current absence from the list already matters; a pending proposal does not establish that an outsourcing facility can continue using bulk semaglutide.
| Who | Today | If FDA finalizes the exclusion |
|---|---|---|
| 503A pharmacy (state-licensed) | Individual-patient and essentially-copy conditions, among other requirements; four-prescription policy is enforcement discretion | Unchanged by the 503B list |
| 503B outsourcing facility | Bulk-substance route lacks the listed shortage or clinical-need basis in the reviewed FDA policy | Proposed noninclusion addresses bulk-substance compounding, not every facility pathway |
| FDA-approved semaglutide products | Sold under their approved labels | Unaffected |
| “Research use only” sellers | FDA warns against products falsely marketed for research while sold for human use | No authorization for human treatment created by the proposal |
Sources: FDA compounding policy page [2], FDA 503B proposal [4], FDA concerns page [3].
Could anything else end 503A compounding? Not on a known schedule. State pharmacy boards oversee 503A pharmacies, and FDA has warned companies that sold semaglutide illegally, including vials falsely labeled “for research purposes” [3]. Tirzepatide is in the same position, with an earlier timeline: see is compounded tirzepatide still available.
What to do if your supply changes
If your program stops offering compounded semaglutide, your prescriber can assess approved alternatives and whether a change is appropriate. The product and prescription need individual assessment; don’t convert doses yourself. Brand offers also require checking the exact product, quantity and eligibility. Right now, NovoCare lists Wegovy pens at $199 a month for new patients at the two lowest doses, for two fills through December 31, 2026, then $349 for the usual injection package; the higher-strength package has a separate price. The tablet offer starts at $149 for 30 initiation-strength tablets, not every maintenance strength. Offers can change or end [7].
How the Wegovy pill works, and whether it fits your routine, is in oral semaglutide. Compounded and brand costs side by side are in how much compounded semaglutide costs, and the legal routes to a prescription are in how to get compounded semaglutide.
How to tell a lawful program from a risky one
- says its compounded drug is the same as an FDA-approved drug
- offers deep discounts or prices that seem too good to be true
- sends medicine that looks different from before, or arrives damaged or without instructions
- doesn’t require a screening and prescription by a licensed doctor
- has no licensed doctor to answer questions after delivery
- prints spelling errors or a wrong pharmacy address on the label
- names a pharmacy you think might be fake
FDA reported 990 adverse-event reports associated with compounded semaglutide through May 31, 2026, and warns of underreporting. These reports do not establish causation or incidence [3]. A secret-shopper study of 75 brick-and-mortar clinics in West Virginia and Oklahoma during 2025 found concerns in its limited supplier assessment, including facilities lacking identified sterile-compounding licenses [8]. Confirming the pharmacy is one check, not a guarantee of product quality or an appropriate prescription. More on what compounded semaglutide is, and how programs compare, is in compounded semaglutide and on the compounded semaglutide providers scorecard.
What to ask your prescriber now
- Which pharmacy fills my prescription, and is it a 503A pharmacy licensed in my state?
- Is my semaglutide the base form, or a sodium or acetate salt?
- What documented reason makes a compounded product right for me instead of Wegovy?
- If the rules change, how would you move me to a brand product, and what would it cost?